REGN - What's Going On With FibroGen Stock Tuesday? | Benzinga
FibroGen Inc (NASDAQ:FGEN) shares initially traded higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical trial supply agreement with Regeneron.
The Details: FibroGen announced that the FDA cleared its IND of FG-3165, allowing the company to initiate a Phase 1 clinical trial.
FG-3165 is a galectin-9 targeted monoclonal antibody under development for treatment of solid tumors characterized by high Gal9 levels of expression. Phase 1 trials evaluating the safety and efficacy of FG-3165 ...